Lipid-lowering therapy intensification guided by apolipoprotein B (apoB) targets
Target Population
Statin-eligible, ASCVD-free US adults
Care Setting
Primary prevention in outpatient clinical settings
Key Highlights
ApoB-guided lipid-lowering therapy intensification yielded the greatest quality-adjusted life-year (QALY) gains compared to LDL-C and non–HDL-C targets.
ApoB strategy prevented the highest number of ASCVD events and was cost-effective with an incremental cost-effectiveness ratio of $30,300 per QALY gained.
Treatment intensification occurred more frequently with apoB targets (64%) than with non–HDL-C (57%) or LDL-C (51%) targets.
Guideline-Based Recommendations
Diagnosis
Use apoB measurement to guide lipid-lowering therapy intensification in primary prevention.
Management
Initiate statin therapy per 2018 AHA/ACC guidelines and intensify treatment to achieve apoB <78.7 mg/dL.
Consider moderate- and high-intensity statins and ezetimibe to achieve lipid targets.
Monitoring & Follow-up
Monitor apoB levels to guide treatment adjustments and assess cardiovascular risk reduction.
Risks
Higher overall costs with apoB strategy are driven by longer life expectancy and extended preventive treatment duration, not by apoB testing costs.
Model assumptions on treatment effects and costs may influence outcomes.
Patient & Prescribing Data
250,000 statin-eligible, ASCVD-free US adults from NHANES data (2005–2016)
ApoB-guided intensification prevented 1,018 ASCVD events and yielded 1,324 additional QALYs compared with non–HDL-C strategy over a lifetime horizon.
Clinical Best Practices
Adopt apoB as a primary target for lipid-lowering therapy intensification in primary prevention to maximize ASCVD event reduction and QALY gains.
Apply treatment intensification thresholds consistent with apoB <78.7 mg/dL to guide therapy adjustments.
Incorporate cost-effectiveness considerations favoring apoB-guided strategies within a health sector perspective.
Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer, and mortality across three large cohorts.
